News

Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non‐executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held numerous leadership positions, including at the board level, to help companies through high phases of growth.

Quotient Sciences to Recapitalize With Global Private Equity Firm Permira

Quotient’s Andy Lewis appointed as Secretary of Controlled Release Society

Quotient Sciences has won the Outstanding Achievement Award at the 2019 Medilink UK Healthcare Business Awards.

Quotient Sciences announced that it has received a Transatlantic Growth Award at a ceremony hosted by BritishAmerican Business in London. The award, in the 'UK SME in the US' category, was presented to Gordon Cameron, CFO, Quotient Sciences.